Celltrion Healthcare Australia Pty

What Celltrion Healthcare Australia Pty does

Celltrion Healthcare Australia Pty Ltd is a wholly-owned Australian subsidiary of Celltrion, Inc. (a publicly traded South Korean biopharmaceutical company listed on the Korea Exchange under ticker 068270). Headquartered in Sydney, the subsidiary serves as the regional sales and marketing office for Australia and New Zealand, distributing a portfolio of 12 biosimilar products including Remsima (infliximab), Truxima (rituximab), Herzuma (trastuzumab), Yuflyma (adalimumab), Vegzelma (bevacizumab), Omlyclo (omalizumab), Steqeyma (ustekinumab), Stoboclo (denosumab), Osenvelt (denosumab), Avtozma (tocilizumab), and Eydenzelt (aflibercept), plus Remsima SC (subcutaneous infliximab). These products target oncology, autoimmune diseases, inflammatory conditions, and allergic conditions.

The parent group operates as a one-stop biopharmaceutical solution provider spanning R&D, clinical trials, regulatory affairs, production, and distribution. Core technology assets include the world's first monoclonal antibody biosimilar development platform, mRNA platform technology, subcutaneous formulation capabilities, and microbiome therapeutics. The parent operates large-scale manufacturing facilities with a combined production capacity of 250,000L across three plants in Incheon, Korea, all US FDA and Europe EMA cGMP certified. The group invests approximately 20% of revenue in R&D annually and has received regulatory approvals in approximately 100 countries.

The Australian subsidiary operates an enterprise field sales model targeting healthcare providers (hospitals, clinics, physicians, pharmacists) across Australia and New Zealand. Revenue is generated through pharmaceutical product sales distributed via direct sales teams and partner distributors, with pricing not publicly disclosed on the Australian website. The subsidiary serves as the regional commercialization channel within the global distribution network that reaches over 100 countries through direct sales offices and channel partners including Adcock Ingram, Hikma, Pfizer, Teva, and others.

Name

Celltrion Healthcare Australia Pty

Legal name

Celltrion Healthcare Australia Pty Ltd

Website

https://celltrionhealthcare.com.au

Company type

Private

Founded year

2002

Operating status

Operating

Short description

Celltrion Healthcare Australia Pty Ltd is a Sydney-based subsidiary of South Korean biopharmaceutical company Celltrion, Inc., distributing 12 biosimilar medicines targeting oncology, autoimmune, and inflammatory conditions to healthcare providers across Australia and New Zealand.

Ownership category

akta.pro rank

Product category

Biosimilar Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

akta.pro secondary industries

Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)

Keywords

• Biopharmaceutical products
• Biosimilar medicines
• Monoclonal antibodies
• Pharmaceutical distribution
• Biologic therapeutics

Headquarters

HQ city

Sydney

HQ country

Australia

HQ region

Oceania

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Marketing or Sales, Personnel

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from the sale of biopharmaceutical products including biosimilars. Products are distributed globally through direct sales network and distribution partners across approximately 100 countries. Manufacturing capabilities support both drug substances and drug products.
2. Global Distribution Network: Direct distribution of multiple antibody products through established global sales and marketing offices across multiple regions including Australia, Europe, Americas, and Asia Pacific

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Celltrion Healthcare Australia distributes a portfolio of biosimilar pharmaceutical products (monoclonal antibody biosimilars) in Australia and New Zealand, including Remsima (infliximab), Truxima (rituximab), Herzuma (trastuzumab), Yuflyma (adalimumab), Vegzelma (bevacizumab), Omlyclo (omalizumab), Steqeyma (ustekinumab), Stoboclo and Osenvelt (denosumab), Avtozma (tocilizumab), and Eydenzelt (aflibercept). As the Australian regional arm of Korean biopharmaceutical company Celltrion Inc., it markets treatments for autoimmune diseases, oncology, and inflammatory conditions through direct sales and medical information services to healthcare professionals.

Product overview

Celltrion Healthcare Australia Pty offers a portfolio of 12 biosimilar products covering oncology, autoimmune, and inflammatory diseases. The product portfolio includes monoclonal antibody biosimilars such as Remsima® (infliximab), Truxima® (rituximab), Herzuma® (trastuzumab), Yuflyma® (adalimumab), Vegzelma® (bevacizumab), Omlyclo® (omalizumab), Steqeyma® (ustekinumab), Stoboclo® (denosumab), Osenvelt®, Avtozma® (tocilizumab), and Eydenzelt® (aflibercept). Additionally, Remsima® SC represents an innovative subcutaneous formulation delivery option. The company positions itself as a global biopharmaceutical one-stop solution provider covering R&D, production, and global distribution.

Differentiator

Problem solved

Functional benefit

Products and services

• Remsima® Infliximab biosimilar for treating autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. Marketed to healthcare providers and patients in Australia and New Zealand.
• Truxima® Rituximab biosimilar for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other conditions.
• Herzuma® Trastuzumab biosimilar for treating HER2-positive breast cancer and gastric cancer.
• Remsima® SC Subcutaneous formulation of infliximab biosimilar providing improved patient convenience with self-administration option for treating autoimmune diseases.
• Yuflyma® Adalimumab biosimilar for treating rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and other autoimmune conditions.
• Vegzelma® Bevacizumab biosimilar for treating various cancers including colorectal cancer, lung cancer, and renal cell carcinoma.
• Omlyclo® Omalizumab biosimilar for treating allergic asthma and chronic spontaneous urticaria.
• Steqeyma® Ustekinumab biosimilar for treating psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
• Stoboclo® Denosumab biosimilar for treating osteoporosis and bone metastases.
• Osenvelt® Biosimilar product (denosumab) for treating osteoporosis.
• Avtozma® Tocilizumab biosimilar for treating rheumatoid arthritis, giant cell arteritis, and cytokine release syndrome.
• Eydenzelt® Aflibercept biosimilar for treating neovascular age-related macular degeneration and other ocular conditions.

Quantifiable outcome

• Reduction of annual treatment cost through biosimilar alternatives
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature5 records

Partnerships

27 partnerships are on record, tiered core and minor.

• Takeda Ltd.coreStrategic or Co-development Partner · 1 August 2020Celltrion acquired Primary Care product assets for Asia Pacific markets from Takeda Ltd. in August 2020, expanding its product portfolio and market presence in the region.
• Adcock IngramminorChannel Partner/ Reseller/ DistributorDistribution partner for pharmaceutical products in certain markets
• HikmaminorChannel Partner/ Reseller/ DistributorDistribution partner for pharmaceutical products in certain markets
• PfizerminorChannel Partner/ Reseller/ DistributorDistribution partner for pharmaceutical products in certain markets
• TevaminorChannel Partner/ Reseller/ DistributorDistribution partner for pharmaceutical products in certain markets
• Orion PharmaminorChannel Partner/ Reseller/ DistributorDistribution partner for pharmaceutical products in certain markets
• Kern Pharma BiologicsminorChannel Partner/ Reseller/ DistributorDistribution partner for pharmaceutical products in certain markets
• iQONE Healthcare SwitzerlandminorChannel Partner/ Reseller/ DistributorDistribution partner for pharmaceutical products in certain markets
• Astra PharmaminorChannel Partner/ Reseller/ DistributorDistribution partner for pharmaceutical products in certain markets
• ATCO PharmaminorChannel Partner/ Reseller/ DistributorDistribution partner for pharmaceutical products in certain markets
• BIOMMminorChannel Partner/ Reseller/ DistributorDistribution partner for pharmaceutical products in certain markets
• George Steuart HealthminorChannel Partner/ Reseller/ DistributorDistribution partner for pharmaceutical products in certain markets
• Laboratorio SavalminorChannel Partner/ Reseller/ DistributorDistribution partner for pharmaceutical products in certain markets
• MediPharm LabsminorChannel Partner/ Reseller/ DistributorDistribution partner for pharmaceutical products in certain markets
• RAFFOminorChannel Partner/ Reseller/ DistributorDistribution partner for pharmaceutical products in certain markets
• SAVAL PharmaceuticalminorChannel Partner/ Reseller/ DistributorDistribution partner for pharmaceutical products in certain markets
• VIANEX S.A. PharmaceuticalminorChannel Partner/ Reseller/ DistributorDistribution partner for pharmaceutical products in certain markets
• PadagisminorChannel Partner/ Reseller/ DistributorDistribution partner for pharmaceutical products in certain markets
• STEIN CORP.minorChannel Partner/ Reseller/ DistributorDistribution partner for pharmaceutical products in certain markets
• C.A.PminorChannel Partner/ Reseller/ DistributorDistribution partner for pharmaceutical products in certain markets
• GAEminorChannel Partner/ Reseller/ DistributorDistribution partner for pharmaceutical products in certain markets
• Medical LogisticsminorChannel Partner/ Reseller/ DistributorDistribution partner for pharmaceutical products in certain markets
• VP VIET PHATminorChannel Partner/ Reseller/ DistributorDistribution partner for pharmaceutical products in certain markets
• KAYAKU Safety Systems EuropeminorChannel Partner/ Reseller/ DistributorDistribution partner for pharmaceutical products in certain markets
• PH OKTAL PHARMAminorChannel Partner/ Reseller/ DistributorDistribution partner for pharmaceutical products in certain markets
• PHARMA KERN BiologicsminorChannel Partner/ Reseller/ DistributorDistribution partner for pharmaceutical products in certain markets
• CHS Community Health SystemsminorChannel Partner/ Reseller/ DistributorDistribution partner for pharmaceutical products in certain markets

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Samsung Bioepis: Samsung Bioepis is a South Korean biosimilar developer commercializing monoclonal antibody biosimilars (Imraldi, Renflexis, Aybintio) with global distribution — the most direct competitor to Celltrion's mAb biosimilar franchise across similar therapeutic areas.
• Alvotech: Alvotech is an Iceland-based biosimilar developer focused on monoclonal antibody biosimilars, including infliximab, adalimumab, and ustekinumab, directly overlapping Celltrion's core product set and competing in the same FDA/EMA regulatory pathways.
• Biocon Biologics: Biocon Biologics is an India-based biosimilar manufacturer with global commercial reach in insulin, mAb biosimilars (Ogivri, Fulphila), and partnership with Viatris — directly competing with Celltrion in oncology and immunology biosimilars.

Broad incumbents

• Amgen: Amgen is a global biopharmaceutical originator that also sells biosimilars (e.g., Amjevita, Kanjinti, Mvasi) through its US infrastructure, competing across oncology and immunology biosimilar categories where Celltrion operates.
• Sandoz (Novartis): Sandoz is the global leader in generic and biosimilar medicines, including Hyrimoz, Erelzi, and Zessly — directly competing with Celltrion's biosimilars across autoimmune and oncology indications globally.
• Pfizer (Biosimilars): Pfizer markets multiple biosimilars (Inflectra, Ruxience, Zirabev, Nivestym) and is also a Celltrion distribution partner in some markets — a competitor and channel partner simultaneously, making it a key comparable.
• Viatris: Viatris (formed via Mylan-Upjohn merger) markets multiple biosimilars (Hulio, Fulphila, Ogivri) globally and previously partnered with Biocon — competing with Celltrion across the same therapeutic areas with established commercial infrastructure.
• Teva Pharmaceutical Industries: Teva is a global pharmaceutical company with a biosimilars portfolio (Truxima distribution in select markets, Herzuma, Ajovy biosimilars under development) and is both a Celltrion distribution partner and a competitor in biosimilar markets.
• Stada Arzneimittel: Stada is a European-focused generic and biosimilar manufacturer with products (e.g., Silapo, Terrosa) that overlap with biosimilars in autoimmune and oncology segments, competing in Celltrion's key European markets.

Emerging players

• Dr. Reddy's Laboratories (Biologics): Dr. Reddy's has a growing biosimilar and biologic manufacturing capability, with products in oncology and immunology that compete in similar therapeutic areas and emerging markets as Celltrion's portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/celltrion-healthcare-australia-pty-ltd

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celltrion Healthcare Australia Pty